Physician profile
Anna Marino
NPI 1124217260
$22,577.82
in general payments reported to CMS, 2019-2025
45 companies · $745 in 2025
The $745 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,974 · 2020: $7,585 · 2021: $1,543 · 2022: $2,181 · 2023: $1,024 · 2024: $526 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,273.47 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $9,932.38 | 2019-2020 | |
| Medtronic Minimed, INC. | $3,033.38 | 2019-2020 | |
| Medtronic, INC. | $2,133.57 | 2021-2025 | Minimed 780g, Minimed 770g |
| Novo Nordisk INC | $1,102.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $1,089.72 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $625.44 | 2019-2023 | Jardiance |
| Dexcom, INC. | $596.55 | 2022-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $463.19 | 2022-2025 | |
| Abbvie INC. | $366.08 | 2019-2023 | |
| Mannkind Corporation | $324.44 | 2020-2022 | |
| Amgen INC. | $304.28 | 2019-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $276.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $259.36 | 2019-2023 | Farxiga |
| Insulet Corporation | $220.31 | 2019-2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.17 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Marino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.